Table 3. Radiographic and pathological assessment.
| Case | SLD change from baseline, % | SUVmax change from baseline, % | y-stage | Therapeutic effecta | Histologyb | P-stage | Pathological response |
|---|---|---|---|---|---|---|---|
| 1 | –68.0 | NA | T1cN2M0, IIIa | PR | SCC | T2bN0M0, IIA | 15–20% tumor residue |
| 2 | –36.6 | –41.4 | T4N2M0, IIIb | PR | SCC | T2N2M0, IIIB | MPR (5% tumor residue) |
| 3 | –37.5 | –37.2 | T3N2M0, IIIb | PR | SCC | T2aN2M0, IIIA | 15–20% tumor residue |
| 4 | –63.6 | NA | T2aN2M0, IIIa | PR | SCC | T2aN0M0, IB | MPR (5% tumor residue) |
| 5 | –38.8 | NA | T1cN2M0, IIIa | PR | SCC | T0N2M0 | MPRc |
| 6 | –30.0 | –68.3 | T3N2M0, IIIb | SD | SCC | T3N0M0, IIA | MPR (<10% tumor residue) |
| 7 | –49.4 | –68.8 | T3N2M0, IIIb | PR | AD | T1aN0M0, IA | MPR (<10% tumor residue) |
| 8 | –33.3 | NA | T1bN2M0, IIIa | PR | AD | T1aN2M0, IIIA | 15–20% tumor residue |
a, therapeutic effect of preoperative treatment according to radiologic response; b, histology post-surgery; c, for the fifth case, the primary tumor achieved PCR, but the lymph node of lower lung ligament was positive. y-stage, clinical stage after neoadjuvant chemoimmunotherapy; P-stage, pathological stage; AD, adenocarcinoma; MPR, major pathological response; NA, not available; PCR, pathologic complete response; PR, partial response; SCC, squamous cell carcinoma; SD, stable disease; SLD, sum of lesion diameter; SUVmax, maximum standardized uptake value.